ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Agilent Technologies has purchased the nucleic acid manufacturing assets of Dowpharma for an undisclosed sum. Agilent, which supplies measurement equipment and other technologies for life sciences research, entered the nucleic acid contract manufacturing arena in 2006 with the purchase of a 33,500-sq-ft current Good Manufacturing Practice-certified facility in Boulder, Colo., from SynPro. The new assets, including large-scale nucleic acid synthesis, purification, and drying capacity from Dow's discontinued oligonucleotide business, will be moved from Midland, Mich. They are due to come on-line in Boulder at the end of 2008.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter